Treatment with Interferon alpha prior to discontinuation of Imatinib in patients with chronic myeloid leukemia

被引：12

作者：

Hardan, Izhar ^{[1
]}

Stanevsky, Anfisa ^{[1
]}

Volchek, Yuliya ^{[1
]}

Tohami, Tali ^{[1
]}

Amariglio, Ninette ^{[1
]}

Trakhtenbrot, Luba ^{[1
]}

Koren-Michowitz, Maya ^{[1
]}

Shimoni, Avichai ^{[1
]}

Nagler, Arnon ^{[1
]}

机构：

[1] Chaim Sheba Med Ctr, Div Hematol, IL-52621 Tel Hashomer, Israel

来源：

CYTOKINE | 2012年 / 57卷 / 02期

关键词：

CML; Imatinib; IFN-alpha; Stopping; CHRONIC MYELOGENOUS LEUKEMIA; COMPLETE MOLECULAR REMISSION; TYROSINE KINASE INHIBITORS; DIAGNOSED CHRONIC-PHASE; FOLLOW-UP; RESPONSES; THERAPY; NILOTINIB; MESYLATE; TRIAL;

D O I：

10.1016/j.cyto.2011.11.018

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Imatinib (IM) is the current first line treatment for chronic myeloid leukemia (CML). However, the disease will progress in the majority of patients pausing IM. IFN-alpha may intensify the response and increase the percentage of patients maintaining remission after IM cessation. Eleven patients with stable (>= 2 years) complete cytogenetic responses (CCyR) on IM therapy were recruited to the study. They were administered Peg-IFN-alpha for 9 months before and for 3 months following IM discontinuation. During the 12 months of Peg-IFN-alpha therapy the remission status improved in five (45%) of the patients. Six (55%) of the patients experienced cytogenetic relapses at a median period of 8 months (range 2-33) after IM withdrawal. All six patients regained CCyR following IM restart. With a median follow up of 47 months (range 35-50), five (45%) out of the 11 studied patients maintain cytogenetic response off IM therapy. The role of Peg-IFN-alpha in patients pausing IM is to be further evaluated. This study is registered with ClinicalTrials.gov, number NCT00297570. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：290 / 293

页数：4

共 24 条

[1] BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria [J].

Branford, Susan ;

Seymour, John F. ;

Grigg, Andrew ;

Arthur, Chris ;

Rudzki, Zbigniew ;

Lynch, Kevin ;

Hughes, Timothy .

CLINICAL CANCER RESEARCH, 2007, 13 (23) :7080-7085

[2] Interferon α and T-cell responses in chronic myeloid leukemia [J].

Burchert, A ;

Neubauer, A .

LEUKEMIA & LYMPHOMA, 2005, 46 (02) :167-175

[3] Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia [J].

Burchert, Andreas ;

Mueller, Martin C. ;

Kostrewa, Philippe ;

Erben, Philipp ;

Bostel, Tilman ;

Liebler, Simone ;

Hehlmann, Ruediger ;

Neubauer, Andreas ;

Hochhaus, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) :1429-1435

[4] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Gathmann, Insa ;

Kantarjian, Hagop ;

Gattermann, Norbert ;

Deininger, Michael W. N. ;

Silver, Richard T. ;

Goldman, John M. ;

Stone, Richard M. ;

Cervantes, Francisco ;

Hochhaus, Andreas ;

Powell, Bayard L. ;

Gabrilove, Janice L. ;

Rousselot, Philippe ;

Reiffers, Josy ;

Cornelissen, Jan J. ;

Hughes, Timothy ;

Agis, Hermine ;

Fischer, Thomas ;

Verhoef, Gregor ;

Shepherd, John ;

Saglio, Giuseppe ;

Gratwohl, Alois ;

Nielsen, Johan L. ;

Radich, Jerald P. ;

Simonsson, Bengt ;

Taylor, Kerry ;

Baccarani, Michele ;

So, Charlene ;

Letvak, Laurie ;

Larson, Richard A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417

[5] IFNα activates dormant haematopoietic stem cells in vivo [J].

Essers, Marieke A. G. ;

Offner, Sandra ;

Blanco-Bose, William E. ;

Waibler, Zoe ;

Kalinke, Ulrich ;

Duchosal, Michel A. ;

Trumpp, Andreas .

NATURE, 2009, 458 (7240) :904-U11

[6] Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia [J].

Giles, F. J. ;

O'Dwyer, M. ;

Swords, R. .

LEUKEMIA, 2009, 23 (10) :1698-1707

[7] Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy [J].

Goh, Hyun-Gyung ;

Kim, Yoo-Jin ;

Kim, Dong-Wook ;

Kim, Hyeoung-Joon ;

Kim, Soo-Hyun ;

Jang, Se-Eun ;

Lee, Jeong ;

Kim, Dongho ;

Kim, Wan-Seok ;

Park, Sa-Hee ;

Kweon, Il-Young .

LEUKEMIA & LYMPHOMA, 2009, 50 (06) :944-951

[8] Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results [J].

Hughes, Timothy ;

Deininger, Michael ;

Hochhaus, Andreas ;

Branford, Susan ;

Radich, Jerald ;

Kaecla, Jaspal ;

Baccarani, Michele ;

Cortes, Jorge ;

Cross, Nicholas C. P. ;

Druker, Brian J. ;

Gabert, Jean ;

Grimwade, David ;

Hehlmann, Ruediger ;

Kamel-Reid, Suzanne ;

Lipton, Jeffrey H. ;

Longtine, Janina ;

Martinelli, Giovanni ;

Saglio, Giuseppe ;

Soverini, Simona ;

Stock, Wendy ;

Goldman, John M. .

BLOOD, 2006, 108 (01) :28-37

[9] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia [J].

Hughes, TP ;

Kaeda, J ;

Branford, S ;

Rudzki, Z ;

Hochhaus, A ;

Hensley, ML ;

Gathmann, I ;

Bolton, AE ;

van Hoomissen, IC ;

Goldman, JM ;

Radich, JP ;

Taylor, K ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Lechner, K ;

Verhoef, G ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shepherd, J ;

Shustik, C ;

Lipton, J ;

Kovacs, DM ;

Turner, AR ;

Nielsen, JL ;

Birgens, H ;

Bjerrum, OW ;

Guilhot, F ;

Reiffers, J ;

Rousselot, P ;

Facon, T ;

Harousseau, JL ;

Tulliez, M ;

Guerci, A ;

Blaise, D ;

Maloisel, F ;

Michallet, M ;

Fischer, T ;

Hossfeld, D ;

Mertelsmann, R ;

Andreesen, R ;

Nerl, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1423-1432

[10] Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies [J].

Jiang, X. ;

Zhao, Y. ;

Smith, C. ;

Gasparetto, M. ;

Turhan, A. ;

Eaves, A. ;

Eaves, C. .

LEUKEMIA, 2007, 21 (05) :926-935

← 1 2 3 →